Welcome to Xi’an Good Doctor Medical Science and Technology Co., Ltd.website ！
Internet Drug Information Service Qualification Certificate: (Shaanxi)-Non-Operating -2023-0143
Thymoma is the most common type of tumor in the anterior mediastinum. The pleura is a hotspot for thymoma metastasis, known as the "host site"; pleural dissemination is a special mode of metastasis for thymoma. Pleural metastasis of thymoma may already exist at the initial diagnosis, representing stage M1a thymoma; or it may appear during follow-up after treatment, representing pleural recurrence (TPR). Surgery is an important treatment method for patients with pleural dissemination or TPR thymoma. Currently, there is no unified opinion on surgical approaches and methods. Simple surgery is difficult to achieve truly complete resection of pleural dissemination or TPR thymoma. Intraoperative hyperthermic intratumoral chemotherapy (HITOC) is an effective supplementary treatment, but internationally, the selection of HITOC regimens and setting of conditions are still under exploration; previous studies were mainly small sample, retrospective, and non-controlled studies with many confounding factors and limited clinical experience. This article summarizes and analyzes the diagnosis and treatment progress of pleural dissemination or TPR thymoma with surgery combined with HITOC, providing a theoretical basis for selecting reasonable treatment methods and formulating individualized treatment strategies.
2025-07-30
Expert Consensus on the Design of an Interventional Clinical Study of Malignant Pleural Effusion
2025-07-10
CACA China Integrated Diagnosis and Treatment Guidelines for Peritoneal Tumors - 2025 Edition
Peritoneal tumors are mainly classified as primary and secondary. Primary tumors originate from the peritoneum; common types include primary peritoneal cancer (Müllerian-type epithelial tumors, mainly serous carcinoma) and malignant peritoneal mesothelioma (MPM). Secondary tumors include various metastatic cancers, peritoneal sarcomatosis (PS), pseudomyxoma peritonei (PMP), and gliomatosis. Clinically, metastatic and epithelial malignant peritoneal tumors are more common, while primary and mesenchymal tumors are relatively rare and considered rare diseases.
2025-07-10
Colorectal cancer is one of the most common malignant tumors in China, ranking second and fourth in incidence and mortality rates among all malignant tumors, respectively. Metastasis and recurrence are the main causes of death in patients with colorectal cancer. The peritoneum is a common site of colorectal cancer metastasis, second only to liver and lung metastasis, but its prognosis is far worse than that of liver and lung metastasis.
2025-07-10
【New Law】Application and Key Points of Thoracic Thermal Perfusion Chemotherapy in Thoracic Treatment
Malignant pleural effusions (MPEs) are mainly seen in patients with advanced lung cancer (37.5%), breast cancer (16.8%), lymphoma (11.5%), genitourinary malignancies (9.4%), and gastrointestinal malignancies (6.9%); the median overall survival time for patients with MPEs and pleural metastases is 3-4 months.
2025-07-10
Among gynecological malignancies, ovarian cancer has the most grim prognosis, primarily due to its high recurrence risk after treatment. Multiple recurrences lead to increased drug resistance. Recurrent ovarian cancer is classified into platinum-sensitive and platinum-resistant types, and treatment strategies depend on the patient's sensitivity to platinum-based chemotherapy. For patients with platinum-sensitive recurrent ovarian cancer, the use of platinum-based chemotherapy combined with targeted therapy (such as PARP inhibitors or bevacizumab) has been shown to prolong survival.
2025-07-10
Hyperthermic intraperitoneal chemotherapy (HIPEC) has been used to treat gastric cancer, but its efficacy in patients with peritoneal metastasis of ovarian cancer remains unclear, hindering the development of rational combination therapies based on hyperthermia (HT).
2025-07-09
The current study was designed to analyze safety of the bedside hyperthermic intra-pleural or intra-peritoneal chemotherapy (HIPEC) from September 2007 to July 2015. Total of 5,759 times of bedside HIPEC in 985 cases of malignant pleural or peritoneal carcinomatosis were analyzed.
2025-07-08
Lili Liu, Tao Zhang, Xiang Song, Cheng-gong Liao, Tengyun Xu, Yang Yang, Ming Zeng, Junmei Jia, Haichuan Su, Yang Song
2025-07-08
Objective: To explore the efficacy of continuous circulating hyperthermic intraperitoneal chemotherapy (HIPEC) at a temperature of 42-43°C for malignant ascites. Method: 45 patients with malignant ascites were randomly divided into two groups. The observation group consisted of 22 patients who underwent conventional puncture to establish a double-channel circulation, first performing peritoneal lavage to replace the intraperitoneal perfusion fluid, and finally maintaining 2500-3500 ml. The continuous circulation at a temperature of 42-43°C began 3-5 minutes later.
2022-08-26
· China Good Doctor ·
· Good friends of human beings ·
Address: Floor 1-2, Left Building No. 1, Huoju Road, East zone of Xi’an High- tech Development District, Xi’an, China
Copyright Xi'an Good Doctor Medical Technology Co., Ltd.
Internet Drug Information Service Qualification Certificate (Shaanxi)-Non-Operating -2023-0143